PoliticsIMPORTANTSeptember 8 at 07:49 AM

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations

StockNow breaking-news AI analysis

AstraZeneca reported Phase III data showing tozorakimab reduced COPD exacerbations by 29% to 34%, supporting management's $3 billion to $5 billion peak annual sales outlook.

1 stocks

AZNAstraZeneca PLC$161.64Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations

What do investors think?

Today's market highlights

Qatar's Foreign Ministry says they are working with its regional partners and China to resume talks with the US and Iran

[MARKET UPDATE] Crude continues to climb, to the detriment of equity futures & fixed income, following the Saudi updates and ahead of the Houthi announcement

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations

Related stocks

What do investors think?

Today's market highlights

Qatar's Foreign Ministry says they are working with its regional partners and China to resume talks with the US and Iran

[MARKET UPDATE] Crude continues to climb, to the detriment of equity futures & fixed income, following the Saudi updates and ahead of the Houthi announcement